MODTX Share Price Performance
SEK 2.40
0.63 (35.59%)
Price SEK 2.40
Share PriceSEK 2.40
MODTX Community Narratives
There are no narratives available yet.
Recent MODTX News & Updates
No updates
Modus Therapeutics Holding AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 07, 2025
- Earnings per share (EPS)
- -0.42
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -737.5%
Modus Therapeutics Holding AB (publ) Competitors
About MODTX
- Founded
- 2011
- Employees
- 2
- CEO
- WebsiteView website
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.
Swedish Market Performance
- 7 Days: -2.2%
- 3 Months: 3.1%
- 1 Year: 3.0%
- Year to Date: -0.9%
Over the last 7 days, the market has dropped 2.2%, driven by a decline of 2.5% in the Industrials sector. Overall the market has been flat in the last year. Looking forward, earnings are forecast to grow by 17% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading